Moderna to Test COVID-19 Booster Candidates Against Omicron Variant
A new booster candidate specific for Omicron is also being planned.
Diagnosis & Disease Information
30 Percent of Hospital-Based Health Care Personnel Unvaccinated
COVID-19 vaccination coverage increased from 36.1% in January to 70% as of September 15.
COVID-19 Vaccine Boosters Appear Effective in Patients With Thoracic Cancer
Seroconversion was observed in 89% of patients who received a third vaccine dose.
Thanksgiving Weekend Brought New COVID-19 Concerns: The Omicron Variant
Cases have been recorded in southern Africa, the European Union, the United Kingdom, and Canada.
Patients Hospitalized With COVID-19 Less Likely to Be Vaccinated
About 84% of COVID-19 hospitalizations were among unvaccinated patients.
FDA Approves Both Pfizer, Moderna Boosters for All Adults
Any adult who received a second dose of either vaccine at least 6 months earlier should be able to get a booster shot.
Two Doses of 10 μg BNT162b2 Safe, Efficacious in 5- to 11-Year-Olds
The Pfizer-BioNTech COVID-19 vaccine had a favorable safety profile in 5- to 11-year-olds.
Prior SARS-CoV-2 Infection Ups Protection for Vaccinated
At 120 days of follow-up, the cumulative infection incidence was higher in vaccinated individuals without prior SARS-CoV-2 infection.
Strong Antibody Response With Moderna COVID-19 Vaccine in Pediatric Trial
The phase 2/3 KidCOVE study is evaluating the mRNA-1273 vaccine in healthy children aged 6 months to less than 12 years.
Breakthrough COVID-19 May Be More Common in Patients With Lymphoid Malignancies
About 81% of patients had lymphoproliferative malignancies.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...